Oral Contraceptives and Hypertension Risk: Implications for Cardiovascular Health and Clinical Management

Oral contraceptives (OCs), commonly utilized for contraception, exert considerable influence on cardiovascular health, especially in the regulation of blood pressure. This review examines the correlation between oral contraceptives, particularly those comprising estrogen and progestin, and their effect on blood pressure. Studies indicate that combination hormonal contraceptives, especially those with high-dose estrogen, raise both systolic and diastolic blood pressure, with risks amplifying according to extended usage, elevated BMI, age, and pre-existing hypertension. Conversely, progestin-only pills (POPs) have negligible effects on blood pressure, rendering them a safer option for women with cardiovascular risk. The fundamental mechanisms encompass estrogen-induced stimulation of the renin-angiotensin-aldosterone system (RAAS) and salt retention, whereas progestin influences mineralocorticoid receptors, resulting in fluid retention and vascular alterations. Meta-analyses demonstrate modest yet significant elevations in blood pressure among oral contraceptive users. Clinicians must meticulously evaluate patient profiles, monitor blood pressure, and contemplate personalized contraceptive options to mitigate cardiovascular risks. Additional randomized controlled trials (RCTs) and longitudinal studies are necessary to improve our comprehension of the effects of oral contraceptives on blood pressure in various populations, highlighting the significance of individualized contraceptive counseling.